Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (3514)	1/2/1998 11:32:00 PM
From: Joe E.	Respond to of 6136

Well that should provide some reading material for those who don't like football.

To: margie who wrote (3514)	1/3/1998 2:24:00 AM
From: John Metcalf	Respond to of 6136

Margie, thanks for all the information and references. Unfortunately, there is a pearls-before-swine reaction here. The question you answered was "who would sponsor trials of Nelfinivir with (CRIX, DMP-366, etc.)" if it doesn't serve company interests. The answers you have provided are that the industry has clinical and scientific integrity, and the trials are being sponsored by NIH, FDA, Aids Clinical Trials Group, and the pharmaceutical companies themselves. It is unfortunate that so many SI participants are accustomed to the penny-stock, management-by-press-release mentality. It is painful to see Agouron, Roche, Merck et.al. cast in the light of the usual SI fodder of SALV, Paracelsian, SOLVEX and AKSEF, and so on. The former are serious companies, treating serious illness, and they report their findings with scientific rigor. I hope the participants here will read and consider the information you have provided. Thank you.